AIOSYN
14.3.2023 13:01:37 CET | Business Wire | Press release
Aiosyn, a software company that develops AI-powered pathology software, has launched its first product that assists digital pathology labs across research, diagnostics and pharma to improve their quality control (QC) process. AiosynQC is an AI-powered algorithm that automatically scans for the most common artifacts that occur during the heterogeneous pre-analytical process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005006/en/
Out-of-focus regions of an H&E stained slide image, blurry and difficult to read, are identified and highlighted with Aiosyn's automated quality control powered by AI. (Photo: Business Wire)
The algorithm of AiosynQC is trained on hematoxylin and eosin (H&E) stained slides. The product helps labs to ensure that only high-quality images are used by pathologists, technicians, and researchers. It can flag cases before presentation to a pathologist, thereby improving the efficiency of the digital pathology workflow by reducing the time that is currently used to manually check for artifacts in whole slide images.
AiosynQC is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. The automated QC is the first product in Aiosyn’s workflow solutions suite. It will be part of a portfolio of deep learning algorithms currently in development for different pathologies for which there is a clear need to improve diagnostic precision and quality.
“AiosynQC will be an important foundational layer and we believe that AI-powered workflow solutions are the entry point for the use and adoption of computational pathology algorithms” according to Patrick de Boer, CEO of Aiosyn.
More information about AiosynQC can be found here.
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice. More about Aiosyn can be found here.
AiosynQC
AiosynQC can only be used in the European Union and the United Kingdom. In the EU and the UK, AiosynQC is not considered a medical device under European IVDR and UK MDR 2002 legislation, respectively. AiosynQC is not intended to be used as an accessory to, nor is it necessary to be used in combination with, any AI or other medical devices to specifically enable them to meet their intended purpose or directly assist in their functionality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab10.3.2026 21:30:00 CET | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — is enhancing regional production and innovation capabilities to better support the continued growth of its Health & Biosciences (H&B) business in Latin America, one of the fastest-growing markets for the company. The effort includes the transformation of the Arroyito site in Argentina into IFF’s first full fermentation‑based enzyme production hub in the region and the opening of a household care application laboratory at IFF’s Innovation Center in Brazil. Together, these enhancements expand IFF’s regional footprint and are expected to improve speed, reliability and locally relevant solutions for markets including brewing, animal nutrition, biofuels and home care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310253993/en/ IFF's home care application lab in Brazil. “This is about turning science into impact where it matte
Andersen offentliggør regnskab for fjerde kvartal og helåret 202510.3.2026 19:52:00 CET | Pressemeddelelse
Andersen Group Inc. (NYSE: ANDG) ("Andersen"), en førende udbyder af uafhængig rådgivning inden for skat, vurdering og finans til private kunder og familiekontorer, virksomheder og fonde i USA, vil offentliggøre sine finansielle resultater for hele året og fjerde kvartal 2025 efter børslukketid tirsdag den 17. marts 2026. Andersens administrerende direktør og bestyrelsesformand, Mark L. Vorsatz, og Andersens økonomidirektør, Neal Livingston, vil afholde en telekonference for at fremlægge Andersens økonomiske resultater tirsdag den 17. marts 2026 kl. 17.00 ET. Deltagere kan følge webcasten på https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3Hvslre. Et link til optagelsen af webcasten vil kunne findes på Andersens Investor Relations-webside på investor.andersen.com inden for et par timer efter begivenheden og vil være tilgængeligt på websiden i seks måneder. Om Andersen Andersen er en førende udbyder af uafhængig rådgivning inden for skat, vurdering og finans til private
Xtep-Sponsored Chinese Teenage Dancer Claims World Championship at Juste Debout Street Dance World Finals10.3.2026 19:46:00 CET | Press release
Xtep, a well-known sportswear brand from China, proudly announced that Xtep-sponsored Chinese teenage dancers delivered an electrifying performance at the Juste Debout Street Dance World Finals in Paris on Sunday, March 8, 2026, claiming top honors and showcasing a unique fusion of traditional Chinese culture with modern street dance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310519224/en/ Chinese Teens Dance to Glory at Juste Debout World Finals Li Yongqiu, a 14-year-old from Southwestern China’s Chongqing Municipality, made history by winning the Global Championship in the Junior Dance Tour, becoming the third Chinese dancer to achieve this feat. His explosive power and technical mastery, honed through years of training that integrates Kungfu elements, captivated judges and audiences alike. The Chinese contingent's success didn't stop there. Zhang Xinlan and Zhang Chuyi secured a Top 8 finish in the Popping Adult D
ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy10.3.2026 18:29:00 CET | Press release
ATLAS anchors H2O America’s equity raise and establishes new substantial shareholdingUpsized transaction highlights strong market support for H2O’s long-term strategy and sector leading growth outlookH2O’s organic growth fully equity funded into 20281 ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”). ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction
TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model10.3.2026 18:22:00 CET | Press release
TIX100 prevented weight regain in mice after semaglutide discontinuation Supports potential role as oral weight maintenance therapy following GLP-1 Receptor Agonist (GLP-1) treatment, addressing a major challenge in long-term obesity management TIXiMED, Inc., a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disorders, is pleased to highlight new research by investigators at the University of Alabama at Birmingham (UAB) Comprehensive Diabetes Center. The study demonstrates that its oral compound, TIX100, effectively prevents weight rebound following discontinuation of GLP-1 treatment in a mouse model of diet-induced obesity. In the study, mice treated with semaglutide experienced significant weight loss of over 13% body weight during a 2-week treatment period while continuing a high-fat diet. Upon discontinuation of semaglutide, untreated mice rapidly regained 14% of their body weight, mi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom